4
Changes in Ownership
Beam Therapeutics Inc. Filed Acc 0001193125-26-033600
CEO sold 50,000 shares at an average $28.87 ($1,443,528)
- CEO acquired 50,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Evans John M. CEO | 2026-01-29 | Option exercise 10b5-1 | +19,336 | $0.67 | $12,955 | 1,006,003 | D |
| Evans John M. CEO | 2026-01-29 | Option exercise 10b5-1 | +5,664 | $0.67 | $3,795 | 1,011,667 | D |
| Evans John M. CEO | 2026-01-29 | Sale 10b5-1 | −16,333 | $29.19 | $476,801 | 995,334 | D |
| Evans John M. CEO | 2026-01-29 | Sale 10b5-1 | −8,667 | $29.74 | $257,781 | 986,667 | D |
| Evans John M. CEO | 2026-01-30 | Option exercise 10b5-1 | +25,000 | $0.67 | $16,750 | 1,011,667 | D |
| Evans John M. CEO | 2026-01-30 | Sale 10b5-1 | −22,094 | $28.27 | $624,672 | 989,573 | D |
| Evans John M. CEO | 2026-01-30 | Sale 10b5-1 | −2,906 | $29.00 | $84,274 | 986,667 | D |
| Derivatives | |||||||
| Evans John M. CEO | 2026-01-29 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −19,336 | 0 | D | ||
| Evans John M. CEO | 2026-01-29 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,664 | 93,672 | D | ||
| Evans John M. CEO | 2026-01-30 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −25,000 | 68,672 | D | ||
| Evans John M. CEO | 2026-01-31 | Grant or award · Stock Option (Right to Buy) 10b5-1 | +180,000 | 180,000 | D | ||
| Open-market sales · 50,000 sh · avg $28.87 · $1,443,528 | |||||||
Loading xslF345X05/ownership.xml…